Lipid Modified CGRP Receptor Antagonists: Balancing Pharmacokinetic Improvement and Potency Loss

Schofield, AL, Rožňovcová, M, D’Aloisio, V, Tan, RKY, Hutcheon, G ORCID: 0000-0002-9786-2074, Cottrell, GS and Coxon, CR Lipid Modified CGRP Receptor Antagonists: Balancing Pharmacokinetic Improvement and Potency Loss. Journal of Medicinal Chemistry. ISSN 0022-2623 (Accepted)

Text Lipid Modified CGRP Receptor Antagonists_Balancing Pharmacokinetic Improvement and Potency Loss.pdf - Accepted Version Access Restricted Available under License Creative Commons Attribution. Download (1MB)

Abstract

Lipidation is a promising strategy for enhancing peptide stability by reducing proteolytic degradation and prolonging systemic exposure. In this study, we systematically evaluated lipid motifs varying in lipid chain length and PEG spacer composition, combined with peptide N-terminal modifications, using a 10-mer calcitonin gene-related peptide receptor antagonist to optimize a candidate for migraine treatment. Incorporation of a C18 diacid lipid motif increased the in vivo (mouse) half-life to 3.5 hours. Although lipidation improved serum stability in a size-dependent manner, it was accompanied by a reduction in receptor antagonism, highlighting the balance between pharmacokinetic enhancement and biological activity. These findings improve our understanding of the trade-offs involved in lipidated peptide design and support future optimization strategies. In addition, we developed a rapid, inexpensive, and HPLC-compatible assay for quantifying peptide binding to human serum albumin, overcoming limitations of conventional equilibrium dialysis methods, including non-specific membrane binding, lengthy equilibration times, and peptide degradation.

Lipidation is a promising strategy for enhancing peptide stability by reducing proteolytic degradation and prolonging systemic exposure. In this study, we systematically evaluated lipid motifs varying in lipid chain length and PEG spacer composition, combined with peptide N-terminal modifications, using a 10-mer calcitonin gene-related peptide receptor antagonist to optimize a candidate for migraine treatment. Incorporation of a C18 diacid lipid motif increased the in vivo (mouse) half-life to 3.5 hours. Although lipidation improved serum stability in a size-dependent manner, it was accompanied by a reduction in receptor antagonism, highlighting the balance between pharmacokinetic enhancement and biological activity. These findings improve our understanding of the trade-offs involved in lipidated peptide design and support future optimization strategies. In addition, we developed a rapid, inexpensive, and HPLC-compatible assay for quantifying peptide binding to human serum albumin, overcoming limitations of conventional equilibrium dialysis methods, including non-specific membrane binding, lengthy equilibration times, and peptide degradation.

Item Type:	Article
Uncontrolled Keywords:	Institute for Health Research (IHR); 0304 Medicinal and Biomolecular Chemistry; 0305 Organic Chemistry; 1115 Pharmacology and Pharmaceutical Sciences; Medicinal & Biomolecular Chemistry; 3214 Pharmacology and pharmaceutical sciences; 3404 Medicinal and biomolecular chemistry; 3405 Organic chemistry
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Pharmacy and Biomolecular Sciences
Publisher:	American Chemical Society
Date of acceptance:	23 October 2026
Date Deposited:	29 Oct 2026 10:15
Last Modified:	29 Oct 2026 10:15
URI:	https://researchonline.ljmu.ac.uk/id/eprint/29756

View Item